PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22+
SponsorEndoQuest Robotics, Inc.

About this trial

The objective of this study is to evaluate the safety and effectiveness of the Endoluminal Surgical (ELS) System in subjects undergoing specified transanal endoluminal procedures in the rectum and sigmoid colon. Subjects will undergo endoscopic submucosal dissection (ESD), with or without closure at the discretion of the Investigator, of benign lesions in the rectum and sigmoid colon.

The safety and effectiveness outcomes will be assessed intraoperatively and postoperatively at discharge and Days 7 and 30.

Eligibility criteria

Qualifiers

Subject is ≥22 years at the time of consent.

Subject has a BMI ≤ 50 kg/m2.

Subject has an ASA score of ≤ 3.

Subject has benign lesion(s) of the rectum or sigmoid colon, such as adenoma (with low- or high-grade dysplasia), neuroendocrine tumor, or other type of polyp as assessed by the most recent colonoscopy/flexible sigmoidoscopy.

Disqualifiers

Subject anatomy is unsuitable for endoscopic visualization or endoluminal surgery.

Subject has active left-sided inflammatory bowel disease.

Subject has an untreated active infection at the time of the procedure.

Subject is considered part of a vulnerable population (e.g., prisoners, mentally disabled).

Trial design

Treatments tested in this trial

  • Endoscopic submucosal dissection using the ELS System

Treatment groups

56 Participants
are divided into 2 treatment groups

Sponsors and collaborators